JP2021514677A5 - - Google Patents
Info
- Publication number
- JP2021514677A5 JP2021514677A5 JP2020568943A JP2020568943A JP2021514677A5 JP 2021514677 A5 JP2021514677 A5 JP 2021514677A5 JP 2020568943 A JP2020568943 A JP 2020568943A JP 2020568943 A JP2020568943 A JP 2020568943A JP 2021514677 A5 JP2021514677 A5 JP 2021514677A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- domain
- cancer
- chimeric cytokine
- inducible chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024029998A JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637600P | 2018-03-02 | 2018-03-02 | |
| US62/637,600 | 2018-03-02 | ||
| PCT/US2019/020340 WO2019169290A1 (en) | 2018-03-02 | 2019-03-01 | Inducible chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029998A Division JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514677A JP2021514677A (ja) | 2021-06-17 |
| JP2021514677A5 true JP2021514677A5 (enExample) | 2022-03-10 |
| JP7526101B2 JP7526101B2 (ja) | 2024-07-31 |
Family
ID=65952060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568943A Active JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
| JP2024029998A Active JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029998A Active JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12163169B2 (enExample) |
| EP (1) | EP3759132A1 (enExample) |
| JP (2) | JP7526101B2 (enExample) |
| KR (2) | KR102842692B1 (enExample) |
| CN (1) | CN111819192A (enExample) |
| AR (1) | AR114273A1 (enExample) |
| AU (2) | AU2019227979B2 (enExample) |
| BR (1) | BR112020017734A2 (enExample) |
| CA (1) | CA3091681A1 (enExample) |
| IL (2) | IL317065A (enExample) |
| MX (2) | MX2020009051A (enExample) |
| SG (1) | SG11202007771VA (enExample) |
| TW (1) | TWI897846B (enExample) |
| WO (1) | WO2019169290A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| AU2019227979B2 (en) * | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| IL328846A (en) * | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| WO2021068068A1 (en) * | 2019-10-08 | 2021-04-15 | Provincial Health Services Authority | Chimeric cytokine receptors |
| CN115315273A (zh) * | 2020-01-14 | 2022-11-08 | 辛德凯因股份有限公司 | Il-2直向同源物及其使用方法 |
| WO2021173586A1 (en) * | 2020-02-24 | 2021-09-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer |
| PE20221757A1 (es) * | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| US20230138428A1 (en) | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| CA3188656A1 (en) * | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| EP4267601A1 (en) * | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| CN117157390A (zh) * | 2021-02-24 | 2023-12-01 | 杭州启函生物科技有限公司 | 用于增强的免疫疗法的系统和组合物及其方法 |
| KR102829018B1 (ko) | 2021-03-03 | 2025-07-04 | 서울대학교산학협력단 | 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도 |
| WO2022213208A1 (en) * | 2021-04-07 | 2022-10-13 | Provincial Health Services Authority | Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| AU2022273049A1 (en) * | 2021-05-14 | 2024-01-04 | Board Of Regents, The University Of Texas System | Chimeric polypeptides and methods of use |
| EP4365295A4 (en) * | 2021-06-28 | 2026-01-07 | Aichi Prefecture | CHIMERIC CYTOKINE RECEPTOR |
| EP4402161A1 (en) * | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2023060126A1 (en) * | 2021-10-06 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Engineered cytokine receptors for tunable adoptive cell therapy |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| WO2024006281A2 (en) * | 2022-06-28 | 2024-01-04 | Carisma Therapeutics Inc. | Switch receptors and modified immune cells |
| EP4554972A1 (en) * | 2022-07-11 | 2025-05-21 | The Board of Trustees of the Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
| CN114949000B (zh) * | 2022-08-02 | 2022-10-04 | 卡瑞济(北京)生命科技有限公司 | 麝香提取物及其增强car-t细胞疗效的应用 |
| CN117683139A (zh) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| JP2026507781A (ja) | 2023-01-23 | 2026-03-06 | メディツィニシェ ホゥーシュル ハノーファー | キメラ抗原受容体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| CN120787258A (zh) | 2023-02-07 | 2025-10-14 | 圭尔医疗有限公司 | Treg细胞培养方法 |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| EP4680748A1 (en) | 2023-03-13 | 2026-01-21 | Arsenal Biosciences, Inc. | Synthetic pathway activators |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| CN121586727A (zh) | 2023-06-21 | 2026-02-27 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| CN121712794A (zh) * | 2023-06-29 | 2026-03-20 | 迪斯派奇生物治疗公司 | 合成细胞因子受体 |
| WO2025026347A1 (en) * | 2023-07-31 | 2025-02-06 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and methods of use thereof |
| WO2025064779A1 (en) * | 2023-09-20 | 2025-03-27 | University Of Southern California | Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others |
| CN122094708A (zh) * | 2023-10-03 | 2026-05-26 | 美国政府(由卫生和人类服务部的部长所代表) | 表达嵌合造血生长因子受体的nk细胞或t细胞及使用方法 |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
| WO2025096643A1 (en) * | 2023-11-01 | 2025-05-08 | Baylor College Of Medicine | Reverse fate receptors to enhance the efficacy of engineered t cells |
| WO2025111277A2 (en) * | 2023-11-20 | 2025-05-30 | Carisma Therapeutics Inc. | Compositions and methods relating to redirected soluble modulators |
| US20260176598A1 (en) | 2024-07-04 | 2026-06-25 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
| WO2026122592A1 (en) * | 2024-12-02 | 2026-06-11 | William Marsh Rice University | Truncated receptors and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| EP2694640B1 (en) * | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2015330017A1 (en) * | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CA2974998C (en) * | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| WO2016168612A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) * | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| CN118546961A (zh) * | 2016-08-26 | 2024-08-27 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| US11654158B2 (en) | 2016-11-17 | 2023-05-23 | 2Seventy Bio, Inc. | TGFBeta signal convertor |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
-
2019
- 2019-03-01 AU AU2019227979A patent/AU2019227979B2/en active Active
- 2019-03-01 CN CN201980016890.6A patent/CN111819192A/zh active Pending
- 2019-03-01 JP JP2020568943A patent/JP7526101B2/ja active Active
- 2019-03-01 KR KR1020207027009A patent/KR102842692B1/ko active Active
- 2019-03-01 EP EP19713907.4A patent/EP3759132A1/en active Pending
- 2019-03-01 CA CA3091681A patent/CA3091681A1/en active Pending
- 2019-03-01 BR BR112020017734-2A patent/BR112020017734A2/pt active IP Right Grant
- 2019-03-01 US US16/290,388 patent/US12163169B2/en active Active
- 2019-03-01 IL IL317065A patent/IL317065A/en unknown
- 2019-03-01 SG SG11202007771VA patent/SG11202007771VA/en unknown
- 2019-03-01 AR ARP190100529A patent/AR114273A1/es unknown
- 2019-03-01 WO PCT/US2019/020340 patent/WO2019169290A1/en not_active Ceased
- 2019-03-01 KR KR1020257025809A patent/KR20250123938A/ko active Pending
- 2019-03-01 MX MX2020009051A patent/MX2020009051A/es unknown
- 2019-03-01 IL IL276831A patent/IL276831B2/en unknown
- 2019-03-04 TW TW108107136A patent/TWI897846B/zh active
-
2020
- 2020-08-31 MX MX2025009955A patent/MX2025009955A/es unknown
-
2024
- 2024-02-29 JP JP2024029998A patent/JP7793667B2/ja active Active
- 2024-10-16 US US18/917,035 patent/US20250333719A1/en active Pending
- 2024-12-04 AU AU2024278090A patent/AU2024278090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276831B1 (en) | Inducible chimeric cytokine receptors | |
| JP2024074801A5 (enExample) | ||
| JP7555625B2 (ja) | 治療用化合物及び方法 | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| TWI809130B (zh) | 嵌合跨膜蛋白及其用途 | |
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| EP3341410B1 (en) | Chimeric antigen receptors with integrated controllable functions | |
| KR102198058B1 (ko) | 면역치료용 조성물 및 방법 | |
| CN114341193A (zh) | 包括tgfβ结合结构域的嵌合细胞因子受体 | |
| CN112955172A (zh) | 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途 | |
| CA2973529A1 (en) | Cll1-specific multi-chain chimeric antigen receptor | |
| JP2018509893A (ja) | キメラ抗原受容体 | |
| CN107428829A (zh) | 靶向g‑蛋白偶联受体的嵌合抗原受体及其用途 | |
| CN113811327A (zh) | MUC1平行CAR(pCAR)治疗剂 | |
| JP2025161810A (ja) | Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞 | |
| US20210070831A1 (en) | Pooling signaling and costimulatory domains in flexible car design | |
| JP2023503840A5 (enExample) | ||
| JP2024511992A (ja) | ガンマデルタｔ細胞刺激 | |
| JP2021514188A (ja) | Ｆｏｘｐ３標的因子組成物と養子細胞療法のための使用方法 | |
| CA3144071A1 (en) | Chimeric protein expressing t-cells | |
| CN118108833A (zh) | 引入外源二硫键的tcr恒定区及其产品和应用 | |
| JP2025506515A5 (enExample) | ||
| WO2026030667A1 (en) | Chimeric antigen receptors targeting the gamma delta t cell receptor | |
| HK1262734A1 (en) | Therapeutic compounds and methods |